positive
Recently
MapLight Therapeutics Soars 23% in Nasdaq Debut After $259 Million IPO
No Image
MapLight Therapeutics debuted on Nasdaq with a 23% gain after a $259 million IPO, signaling revived appetite for biotech equity offerings.
Biotechnology firm MapLight Therapeutics surged 23% on its first trading day following a $258.9 million initial public offering on Nasdaq. The San Francisco-based company priced shares at $17, giving it a post-IPO valuation of approximately $787 million. The proceeds will fund clinical trials for its neurodegenerative drug pipeline. Analysts said MapLight’s strong debut marks renewed investor interest in biotech listings after a sluggish IPO environment earlier this year. The stock closed well above its offer price, outperforming broader healthcare benchmarks.